Skip to content
Trial Eligibility
Menu

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

NCT05208190

This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .

Summary

Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Eligibility basics and study details

Study type
Interventional
Phase
Phase 4
Ages
18 to 65 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
New York State Psychiatric Institute
Last updated on ClinicalTrials.gov
May 4, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 1

  • University of California, Los Angeles · Los Angeles, CA

Georgia · 1

  • Augusta University Research Institute, Inc. · Augusta, GA

Maryland · 1

  • University of Maryland School of Medicine · Baltimore, MD

New York · 3

  • Manhattan Psychiatric Center · New York, NY
  • New York State Psychiatric Institute · New York, NY
  • NYU Langone Medical Center · New York, NY

North Carolina · 1

  • University of North Carolina at Chapel Hill · Chapel Hill, NC

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.